FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)

J Hepatol. 2021 Jan;74(1):247-248. doi: 10.1016/j.jhep.2020.06.040. Epub 2020 Sep 29.

Authors

Yinlian Wu¹, Rahul Kumar², Jiaofeng Huang¹, Mingfang Wang¹, Yueyong Zhu¹, Su Lin³

Affiliations

¹ Liver Research Center of the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China, 350001.
² Department of Gastroenterology and Hepatology, Duke-NUS academic Medical Centre, Changi General Hospital, Singapore.
³ Liver Research Center of the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China, 350001. Electronic address: sumer5129@fjmu.edu.cn.

PMID: 32994079
DOI: 10.1016/j.jhep.2020.06.040

No abstract available

Keywords: FIB-4; Metabolic associated fatty liver disease; Nonalcoholic fatty liver disease.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aspartate Aminotransferases
Humans
Non-alcoholic Fatty Liver Disease* / complications
Non-alcoholic Fatty Liver Disease* / diagnosis

Substances

Aspartate Aminotransferases